The impact of antimicrobial resistance on the treatment of sexually transmitted diseases.
The focus of this article is to review the development of antimicrobial resistance among several sexually transmitted diseases (STDs) and to discuss the frequency and mechanisms of resistance and recommendations for treatment of selected STDs in which resistance to certain antimicrobial agents has increased. For a number of STDs, such as Chlamydia trachomatis and syphilis, no evidence of antimicrobial resistance has developed over the years, although management of these diseases, such as in the case of pelvic inflammatory disease or syphilis in HIV-infected individuals, requires intensive treatment and follow-up to ensure effectiveness of treatment.
Erbelding
E
E
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Quinn
T C
TC
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000994:Antitrichomonal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002602:Chancroid / Q000188:drug therapy / Q000453:epidemiology; D016903:Drug Monitoring; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006069:Gonorrhea / Q000188:drug therapy / Q000453:epidemiology; D006558:Herpes Genitalis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D012749:Sexually Transmitted Diseases / Q000188:drug therapy* / Q000453:epidemiology; D014245:Trichomonas Infections / Q000188:drug therapy / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000994:Antitrichomonal Agents; D000998:Antiviral Agents; D024841:Fluoroquinolones